Intraaortic Balloon Pump vs Peripheral Ventricular Assist Device Use in the United States
| Autor: | Boback Ziaeian, James W. Antonios, Ramtin Anousheh, Behdad Kavianpour, Peyman Benharash, Yas Sanaiha |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Percutaneous business.industry medicine.medical_treatment Cardiogenic shock Retrospective cohort study Odds ratio 030204 cardiovascular system & hematology medicine.disease Confidence interval Clinical trial 03 medical and health sciences 0302 clinical medicine 030228 respiratory system Ventricular assist device Internal medicine Shock (circulatory) medicine Cardiology Surgery medicine.symptom Cardiology and Cardiovascular Medicine business |
| Zdroj: | The Annals of Thoracic Surgery. 110:1997-2005 |
| ISSN: | 0003-4975 |
| DOI: | 10.1016/j.athoracsur.2020.03.129 |
| Popis: | Background The objective of this study was to characterize practical use trends and outcomes for intraaortic balloon pump (IABP) and percutaneous left ventricular assist device (pVAD) use in cardiogenic shock at a national level. Methods An analysis of all adult patients admitted nonelectively for cardiogenic shock from January 2008 through December 2017 was performed using the National Inpatient Sample. Trends of inpatient IABP and pVAD use were analyzed using survey-weighted estimates and the modified Cochran-Armitage test for significance. Multivariable regression models and inverse probability of treatment weights were used to perform risk-adjusted analyses of pVAD mortality, a composite of adverse events (AE), and resource use, with IABP as reference. Results Of an estimated 774,310 patients admitted with cardiogenic shock, 143,051 received a device: IABP, 127,792 (16.5%); or pVAD, 15,259 (2.0%). IABP use decreased (23.8% to 12.7%; P for trend Conclusions Over the study period, the rate of pVAD use for cardiogenic shock significantly increased. Compared with IABP, pVAD use was associated with increased mortality, higher costs, and several AEs. Multi-institutional clinical trials with rigorous inclusion criteria are warranted to evaluate the clinical utility of pVADs in the modern era. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|